FDA Expands Indication for AbbVie’s Antiviral as First Treatment for People With Acute Hepatitis C
This week, the FDA approved a label expansion for glecaprevir/pibrentasvir (Mavyret), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients 3 years and older with acute or chronic hepatitis C (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, glecaprevir/pibrentasvir is the […]
Communicable disease threats report, 7-13 June 2025, week 24
Surveillance and monitoring 13 Jun 2025 Publication series: Communicable Disease Threats Report (CDTR) Time period covered: 7-13 June 2025 Take our survey Share your feedback in our short survey and help us improve publications at ECDC. Your input is valuable! The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health […]
FDA Expands Moderna’s mRNA-1345 RSV Vaccine to Younger Adults
The FDA has expanded the approval of Moderna’s mRNA-1345 RSV vaccine to include people aged 18-59 years. This comes after last year’s initial approval of the vaccine for seniors 60 years of age and older in prevention of lower respiratory tract disease caused by RSV infection.1 “RSV poses a serious health risk to adults with […]
Early Release – Role of Nonpharmaceutical Interventions during 1918–1920 Influenza Pandemic, Alaska, USA – Volume 31, Number 7—July 2025 – Emerging Infectious Diseases journal
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Centre for Research on Pandemics & Society, Oslo Metropolitan University, Oslo, Norway (U. Khakurel, S.-E. Mamelund); University of Missouri, Columbia, Missouri, USA (L. Sattenspiel) During […]
